Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1117-1120

  Schneider, Bryan J ^a,f   Gadgeel, Shirish M ^b   Ramnath, Nithya ^c   Wozniak, Antoinette J ^b   Dy, Grace K ^d   Daignault, Stephanie ^e   Kalemkerian, Gregory P ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f NONE   (United States)

Author keywords

Maintenance; Small cell lung cancer; Sunitinib

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PLATINUM DERIVATIVE; SUNITINIB;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TASTE; THROMBOCYTOPENIA; THYROID DISEASE;

EID: 79958111411     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821529c3     Document Type: Article

References (21)

1. Tas F, Duranyildiz D, Oguz H, et al. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24:492-496. (Pubitemid 44576401)
2. Lucchi M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002; 21:1105-1110.
3. Tanno S, Ohsaki Y, Nakanishi K, et al. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004;46:11-19. (Pubitemid 39201379)
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
5. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989;10:1-10. (Pubitemid 19099520)
6. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-92.
7. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043. (Pubitemid 46622112)
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
9. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478.
10. Johnson BE, Fischer T, Fisher B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003;9:5880-5887. (Pubitemid 38018071)
11. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 2005;103:2128-2131. (Pubitemid 40605121)
12. Schneider BJ, Kalemkerian GP, Ramnath N, et al. Phase II Trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small cell lung cancer. Clin Lung Cancer 2010;11:223-227.
13. Mendel DB, Laird AD, Xin X, et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2002;9:327-337. (Pubitemid 36109749)
14. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009;15:5902-5909.
15. Chen H, Isozaki K, Kinoshita K, et al. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 2003;105:130-135. (Pubitemid 36418498)
16. Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004;4202-4209. (Pubitemid 39620175)
17. Pietras K, Hanahan D. A multitargeted, metronomic, and maximumtolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952. (Pubitemid 46202314)
18. Ready N, Dunphy F, Pang H, et al. Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. Proc Am Soc Clin Oncol 2010;28:15s (abstract 7056).
19. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-3748.
20. Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18f-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009;20:439-445.
21. Toner GC, Mitchell PL, De Boer R, et al. PET imaging study of SU11248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003;22:191 (abstract 767).